Outlook Therapeutics Prices $55 Mln Offering To Support LYTENAVA Launch; Stock Down
(RTTNews) - Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company, priced a public offering of 55.56 million shares and accompanying warrants to purchase up to 55.56 million shares at a combined public offering price of $0.99 for each share of common stock and accompanying warrant. …